echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Servier mutant IDH1/2 enzyme dual inhibitor vorasidenib shows efficacy

    Servier mutant IDH1/2 enzyme dual inhibitor vorasidenib shows efficacy

    • Last Update: 2021-08-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Servier recently announced that the results of a phase 1 dose-escalation clinical study (NCT02481154) evaluating vorasidenib as a single agent for the treatment of isocitrate dehydrogenase (IDH) mutant advanced solid tumors (including low-grade gliomas, LGG) have been published In the famous international cancer research journal "Clinical Cancer Research"


    In the first human study (NCT02481154), a total of 93 patients with advanced solid tumors with IDH1/2 mutations were enrolled, including 52 patients with gliomas


    The results showed that vorasidenib showed good safety at a once-daily dose of <100 mg, and showed preliminary clinical activity in patients with relapsed or progressive IDH1/2 mutations in low-grade gliomas


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.